|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/4965 | |
| A61K 31/497 | |||
| C07D 403/12 | |||
| A61P 35/00 |
| (11) | Number of the document | 3104860 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15746362.1 |
| Date of filing the European patent application | 2015-02-09 | |
| (97) | Date of publication of the European application | 2016-12-21 |
| (45) | Date of publication and mention of the grant of the patent | 2020-12-30 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/015030 |
| Date | 2015-02-09 |
| (87) | Number | WO 2015/120390 |
| Date | 2015-08-13 |
| (30) | Number | Date | Country code |
| 201402277 | 2014-02-10 | GB | |
| 201462083687 P | 2014-11-24 | US |
| (72) |
BOYLE, Robert George, GB
WALKER, David Winter, GB
BOYCE, Richard Justin, GB
PETERSON, Scott, US
FAROUZ, Francine, US
VO, Cong Hung, US
|
| (73) |
Sentinel Oncology Limited,
181 Science Park Milton Road, Cambridge Cambridgeshire CB4 0GJ,
GB
|
| (54) | PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS |
| PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS |